A Study of YL242 in Subjects With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT07197827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors.
Study identification
- NCT ID
- NCT07197827
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Enrollment
- 424 participants
Conditions and interventions
Conditions
Interventions
- YL242 Drug
- YL242; 5-FU; LV Drug
- YL242; Pembrolizumab Drug
- YL242; Pembrolizumab; 5-FU Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 21, 2025
- Primary completion
- Aug 31, 2028
- Completion
- Oct 31, 2028
- Last update posted
- Dec 23, 2025
2025 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| US-201 | New Haven | Connecticut | 06519 | Not yet recruiting |
| US-202 | Sarasota | Florida | 34232 | Recruiting |
| US-204 | Boston | Massachusetts | 02215 | Not yet recruiting |
| US-206 | Grand Rapids | Michigan | 49546 | Recruiting |
| US-205 | Nashville | Tennessee | 37203 | Recruiting |
| US-203 | Houston | Texas | 77030 | Not yet recruiting |
| US-207 | San Antonio | Texas | 78229 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07197827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 23, 2025 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07197827 live on ClinicalTrials.gov.